In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.
Loracarbef (LY163892) is a new beta-lactam antibiotic with in vitro activity similar to those of cefaclor and amoxicillin-clavulanate potassium and superior to that of cephalexin (4, 11, 19) . Loracarbef is absorbed well from the bowel, attaining high levels above the MICs for susceptible organisms in plasma; it is excreted mostly in the urine in the active form. Loracarbef is resistant to plasmid-mediated 1-lactamases and has greater biochemical stability than cefaclor (3, 21, 22 Two clean-catch midstream urine specimens were obtained within 48 h before treatment for analysis and culture. Specimens were collected from genitals and recta with Culturette rayon-tipped swabs (Scientific Products Div., Evanston, Ill.) for nonquantitative aerobic culture pretherapy and 5 to 9 days posttherapy.
Urinary bacterial isolation was performed and quantitative counts were determined as previously described (8, 16, 20, 26) . Antibiotic susceptibility was tested by the disk diffusion method by using 30-R,g disks of loracarbef and 30-p.g disks of cephalothin (1) . Bacterial (Table 1) . Ninetysix percent of the urinary pathogens were susceptible to loracarbef, and 95% were susceptible to cefaclor. The 74 E. coli isolates were all susceptible to loracarbef and cefaclor. Four of five isolates of Enterobacter aerogenes were resistant to both agents. These results are in agreement with previous reports that loracarbef and cefaclor have comparable in vitro activities that are superior to that of cephalexin (2, 4, 11) . In the loracarbef group, 52 of 53 patients had sterile urine cultures after 2 to 4 days of therapy. One patient had a resistant pathogen pretherapy, and her urine culture remained positive. Her therapy was discontinued, as was that of three others, for the following reasons: one because of a low pretherapy bacterial count and two because of adverse reactions. In the cefaclor group, all 55 patients had sterile urine cultures after 2 to 4 days of therapy. Of the patients returning at 5 to 9 days posttherapy, 96% of the loracarbef group and 90% of the cefaclor group had short-term cures. Long-term cures occurred in 81% of the patients initially enrolled in each group who were available for long-term follow-up. Bacteriologic responses through 4 weeks posttherapy are shown in Table 2 . Initially identified urinary pathogens remained eradicated at 4 to 6 weeks posttherapy in 37 (90%) and 39 (93%) of the patients in the loracarbef and cefaclor groups, respectively (P > 0.10). The therapeutic results of the two groups were favorable and comparable to those previously attained with antimicrobial agents, including cephalosporins, in young women (6, 10, (12) (13) (14) (16) (17) (18) .
Periurethral, vaginal, and rectal specimens were obtained from 46 patients in the loracarbef group and 51 patients in the cefaclor group. After therapy in both groups, the numbers of patients with cultures positive for colonizing E. coli in the periurethral (P < 0.001), vaginal (P < 0.001), and rectal (P < 0.01) flora were reduced. No significant change occurred in either (i) the number of patients with positive cultures for other members of the family Enterobacteriaceae or (ii) the susceptibility patterns of the bacteria colonizing these sites in either group. The findings related to cefaclor are in agreement with those previously reported (17, 18) .
In the loracarbef group, five patients experienced adverse events: therapy was discontinued for two patients because of nausea, headache, and abdominal pain; two had nausea, one combined with a rash; and one experienced difficulty breathing and diarrhea on the last day of therapy. In the cefaclor group, three patients reported adverse events: two experienced diarrhea, one with nausea, and one developed a rash on the last day of therapy. Therapy was not interrupted for these three patients.
By 5 to 9 days posttherapy, Candida vaginitis developed in 8 (15.1%) of the patients in the loracarbef group and 11 (20.0%) of the patients in the cefaclor group. Laboratory test results did not significantly change for any patients in either group. These findings are consistent with those previously reported for cefaclor (13-15, 17, 18, 24, 25, 27, 28) .
In conclusion, loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of UTIs in women.
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